AYTU RSI Chart
Last 7 days
-10.1%
Last 30 days
2.4%
Last 90 days
-7.3%
Trailing 12 Months
53.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 93.8M | 0 | 0 | 0 |
2023 | 104.1M | 107.4M | 101.8M | 98.5M |
2022 | 92.7M | 96.7M | 102.4M | 105.6M |
2021 | 57.0M | 65.6M | 74.0M | 82.0M |
2020 | 14.5M | 27.6M | 39.7M | 51.7M |
2019 | 6.5M | 7.3M | 7.3M | 8.7M |
2018 | 3.6M | 3.7M | 4.0M | 4.8M |
2017 | 3.3M | 3.3M | 3.3M | 3.4M |
2016 | 1.8M | 2.6M | 2.8M | 3.1M |
2015 | 110.2K | 261.8K | 721.6K | 1.2M |
2014 | 31.7K | 45.3K | 76.7K | 92.5K |
2013 | 33.6K | 41.8K | 18.1K | 0 |
2012 | 0 | 0 | 17.2K | 25.4K |
2011 | 0 | 0 | 0 | 0 |
2010 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 31, 2024 | pyszczymuka greg | acquired | - | - | 208 | chief commercial officer |
Dec 31, 2023 | pyszczymuka greg | acquired | - | - | 209 | chief commercial officer |
Sep 30, 2023 | pyszczymuka greg | acquired | - | - | 208 | chief commercial officer |
Aug 16, 2023 | jain abhinav | acquired | - | - | 6,500 | - |
Aug 11, 2023 | liu vivian h | acquired | - | - | 1,500 | - |
Aug 11, 2023 | jain abhinav | acquired | - | - | 1,500 | - |
Aug 11, 2023 | dockery carl | acquired | - | - | 1,500 | - |
Aug 11, 2023 | donofrio john jr. | acquired | - | - | 1,500 | - |
Jun 30, 2023 | pyszczymuka greg | acquired | - | - | 208 | chief commerical officer |
Jun 16, 2023 | pyszczymuka greg | bought | 22,428 | 1.869 | 12,000 | chief commerical officer |
Which funds bought or sold AYTU recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | reduced | -24.29 | -753 | 3,222 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 37,012 | 37,012 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | unchanged | - | 2,776 | 42,201 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -24.73 | -2,000 | 8,000 | -% |
May 15, 2024 | Stonepine Capital Management, LLC | unchanged | - | 94,494 | 1,436,310 | 1.14% |
May 15, 2024 | Nantahala Capital Management, LLC | reduced | -50.00 | -2,869,180 | 3,303,910 | 0.19% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 32.54 | 2,715 | 9,199 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 152 | 152 | -% |
May 14, 2024 | NORTHERN TRUST CORP | reduced | -0.03 | 2,902 | 44,275 | -% |
May 14, 2024 | NewEdge Advisors, LLC | unchanged | - | 4.00 | 64.00 | -% |
Unveiling Aytu BioScience Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Aytu BioScience Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Aytu BioScience Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -21.5% | 17,993 | 22,934 | 22,099 | 30,732 | 22,733 | 26,279 | 27,655 | 27,448 | 24,199 | 23,125 | 21,897 | 23,482 | 13,483 | 15,147 | 13,520 | 14,861 | 8,156 | 3,175 | 1,440 | 1,716 | 2,378 |
Cost Of Revenue | - | - | - | - | - | 9,990 | 8,986 | 9,623 | 12,606 | 11,513 | 10,826 | 9,441 | 12,183 | 13,935 | 6,251 | 4,063 | 5,301 | 1,999 | 606 | 376 | 649 | 617 |
Gross Profit | -27.8% | 11,693 | 16,203 | 14,784 | 18,564 | 12,743 | 17,293 | 18,032 | 14,842 | 12,686 | 12,299 | 12,456 | 11,299 | -452 | 8,896 | 9,457 | - | - | - | - | - | - |
Costs and Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 39,148 | 20,722 | - | - | 12,950 | 8,142 | - | - | - |
Operating Expenses | 2.3% | 14,157 | 13,839 | 16,288 | 18,395 | 21,301 | 24,161 | 19,840 | 32,058 | 66,107 | 23,593 | 40,155 | 35,371 | 25,214 | 14,471 | 13,014 | 13,215 | 12,950 | 8,142 | 6,175 | 6,296 | 6,676 |
S&GA Expenses | -0.4% | 6,549 | 6,576 | 7,422 | 7,982 | 12,804 | 10,560 | 10,102 | 10,013 | 9,743 | 9,660 | 9,297 | 12,180 | 6,597 | 5,705 | 5,826 | -8,770 | 9,190 | 6,516 | 5,146 | 4,896 | 5,369 |
R&D Expenses | 18.1% | 619 | 524 | 604 | 465 | 856 | 1,710 | 1,064 | 3,253 | 3,282 | 4,475 | 1,652 | 4,764 | 390 | 286 | 183 | 1,499 | 79.00 | 67.00 | 78.00 | 175 | 109 |
EBITDA Margin | 98.8% | 0.00* | -0.05* | -0.11* | -0.04* | -0.18* | -0.61* | -0.68* | -0.99* | -1.04* | -0.85* | -0.93* | -0.72* | -0.09* | - | - | - | - | - | - | - | - |
Interest Expenses | 22.6% | 994 | 811 | 1,359 | 951 | 840 | 1,456 | 565 | 68.00 | 724 | 668 | 1,688 | 800 | 142 | 59.00 | 248 | 253 | 539 | 447 | 195 | 137 | 195 |
Income Taxes | -70.4% | 245 | 828 | - | - | - | - | - | - | - | -3.00 | -107 | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -534.5% | -2,642 | 608 | -8,120 | -2,457 | -7,200 | -6,693 | -701 | -16,089 | -53,291 | -11,551 | -27,958 | -18,739 | -25,460 | -9,525 | -4,306 | - | - | - | - | - | - |
EBT Margin | 22.8% | -0.13* | -0.17* | -0.24* | -0.16* | -0.29* | -0.73* | -0.80* | -1.13* | -1.20* | -1.02* | -1.10* | -0.88* | -0.24* | - | - | - | - | - | - | - | - |
Net Income | -1212.3% | -2,887 | -220 | -8,120 | -2,457 | -7,200 | -6,693 | -701 | -16,089 | -53,291 | -11,548 | -27,851 | -18,998 | -25,460 | -9,525 | -4,306 | -3,145 | -5,332 | -214 | -4,929 | -14,531 | -4,495 |
Net Income Margin | 20.1% | -0.15* | -0.18* | -0.24* | -0.16* | -0.29* | -0.73* | -0.80* | -1.13* | -1.20* | -1.02* | -1.11* | -0.89* | -0.74* | - | - | - | - | - | - | - | - |
Free Cashflow | -88.1% | -254 | -135 | 5,639 | 15,215 | 2,956 | 3,398 | -3,298 | -1,222 | -3,265 | -2,972 | 2,059 | -427 | 25,550 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -1.8% | 129 | 131 | 133 | 136 | 147 | 141 | 150 | 138 | 169 | 224 | 228 | 266 | 272 | 167 | 141 | 153 | 159 | 74.00 | 31.00 | 35.00 | 38.00 |
Current Assets | -0.3% | 71.00 | 71.00 | 71.00 | 73.00 | 78.00 | 71.00 | 74.00 | 60.00 | 78.00 | 88.00 | 89.00 | 105 | 100 | 93.00 | 65.00 | 75.00 | 83.00 | 18.00 | 12.00 | 15.00 | 18.00 |
Cash Equivalents | 1.4% | 20.00 | 20.00 | 20.00 | 23.00 | 19.00 | 20.00 | 24.00 | 19.00 | 28.00 | 35.00 | 40.00 | 50.00 | 47.00 | 62.00 | 38.00 | 48.00 | 62.00 | 5.00 | 7.00 | 11.00 | 15.00 |
Inventory | 1.5% | 13.00 | 13.00 | 13.00 | 12.00 | 14.00 | 13.00 | 13.00 | 11.00 | 14.00 | 17.00 | 16.00 | 16.00 | 17.00 | 7.00 | 11.00 | 10.00 | 4.00 | 2.00 | 1.00 | 1.00 | 2.00 |
Net PPE | -14.2% | 1.00 | 1.00 | - | 2.00 | - | - | - | - | - | - | - | - | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Goodwill | - | - | - | - | - | - | - | - | - | 9.00 | 46.00 | 46.00 | 66.00 | 38.00 | 28.00 | 28.00 | 28.00 | 24.00 | 15.00 | - | - | - |
Liabilities | - | - | - | 101 | 97.00 | 106 | 96.00 | 102 | 93.00 | 108 | 118 | 116 | 128 | 128 | 54.00 | 50.00 | 58.00 | 73.00 | 57.00 | 29.00 | 28.00 | 22.00 |
Current Liabilities | 30.4% | 84.00 | 64.00 | 65.00 | 69.00 | 85.00 | 67.00 | 73.00 | 64.00 | 80.00 | 101 | 98.00 | 109 | 84.00 | 26.00 | 22.00 | 29.00 | 42.00 | 16.00 | 6.00 | 5.00 | 5.00 |
Short Term Borrowings | 54.1% | 2.00 | 1.00 | 1.00 | 2.00 | 10.00 | 7.00 | - | 4.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt | -100.0% | - | 15.00 | 15.00 | 15.00 | 11.00 | 15.00 | 14.00 | 14.00 | 14.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | 8.00 | 23.00 | - | - | 5.00 |
LT Debt, Current | 38707.7% | 15.00 | 0.00 | - | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 15.00 | - | 15.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -6.3% | 31.00 | 33.00 | 32.00 | 39.00 | 41.00 | 46.00 | 48.00 | 44.00 | 58.00 | 106 | 112 | 138 | 143 | 113 | 91.00 | 95.00 | 86.00 | 17.00 | 2.00 | 7.00 | 16.00 |
Retained Earnings | -0.9% | -315 | -312 | -312 | -304 | -301 | -294 | -287 | -287 | -270 | -217 | -206 | -178 | -159 | -133 | -124 | -120 | -116 | -111 | -111 | -106 | -91.86 |
Additional Paid-In Capital | 0.2% | 346 | 345 | 344 | 343 | 343 | 340 | 336 | 331 | 329 | 323 | 318 | 316 | 302 | 247 | 215 | 215 | 203 | 129 | 114 | 113 | 108 |
Shares Outstanding | 0.0% | 6.00 | 6.00 | 6.00 | 6.00 | 4.00 | 3.00 | 3.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | 12.00 | - | - | - | 38.00 | - | - | - | 88.00 | - | - | - | 10.00 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -88.1% | -254 | -135 | -211 | 9,365 | -2,894 | -2,452 | -9,148 | -7,072 | -9,115 | -8,822 | -3,791 | -6,277 | 19,700 | -2,917 | -7,983 | -7,764 | 20,600 | -6,099 | -2,987 | -3,473 | -3,310 |
Share Based Compensation | -1.1% | 811 | 820 | 930 | 900 | 902 | 3,067 | 1,177 | 1,230 | 1,270 | 1,229 | 1,519 | 1,089 | 1,522 | 508 | 455 | 488 | 263 | 162 | 165 | 299 | 377 |
Cashflow From Investing | 74.1% | -45.00 | -174 | -76.00 | -155 | 1.00 | -5.00 | 42.00 | -41.00 | -70.00 | -3,051 | -86.00 | -2,426 | -317 | -30.00 | -9.00 | -45.27 | 344 | -4,912 | -1,042 | -96.11 | -105 |
Cashflow From Financing | 520.6% | 530 | -126 | -2,734 | -5,404 | 2,583 | -1,865 | 13,557 | -1,117 | 1,521 | 6,590 | -5,464 | 11,814 | -6,398 | 27,076 | -2,178 | -6,372 | 68,183 | 9,258 | - | 117 | 259 |
Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
Net revenue | $ 17,993 | $ 22,733 | $ 63,026 | $ 76,667 |
Cost of sales | 6,300 | 9,990 | 20,346 | 28,599 |
Gross profit | 11,693 | 12,743 | 42,680 | 48,068 |
Operating expenses: | ||||
Selling and marketing | 6,549 | 12,804 | 20,547 | 33,466 |
General and administrative | 5,442 | 7,177 | 17,837 | 22,517 |
Research and development | 619 | 856 | 1,747 | 3,630 |
Amortization of intangible assets | 1,303 | 1,198 | 3,909 | 3,593 |
Restructuring costs | 244 | 0 | 244 | 0 |
Impairment expense | 0 | 0 | 0 | 2,600 |
Gain from contingent consideration | 0 | (734) | 0 | (504) |
Total operating expenses | 14,157 | 21,301 | 44,284 | 65,302 |
Loss from operations | (2,464) | (8,558) | (1,604) | (17,234) |
Other expense, net | (1,195) | (1,215) | (3,083) | (3,527) |
Gain (loss) on derivative warrant liabilities | 1,017 | 2,573 | (5,467) | 6,167 |
Loss before income tax | (2,642) | (7,200) | (10,154) | (14,594) |
Income tax expense | (245) | 0 | (1,073) | 0 |
Net loss | $ (2,887) | $ (7,200) | $ (11,227) | $ (14,594) |
Basic and diluted weighted-average common shares outstanding (in shares) | 5,533,555 | 3,726,779 | 5,511,089 | 3,099,130 |
Basic and diluted net loss per common share (in dollars per share) | $ (0.52) | $ (1.93) | $ (2.04) | $ (4.71) |
Unaudited Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Jun. 30, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 19,760 | $ 22,985 |
Accounts receivable, net | 29,925 | 28,937 |
Inventories | 13,193 | 11,995 |
Prepaid expenses | 7,249 | 8,047 |
Other current assets | 1,003 | 868 |
Total current assets | 71,130 | 72,832 |
Non-current assets: | ||
Property and equipment, net | 967 | 1,815 |
Operating lease right-of-use assets | 1,795 | 2,054 |
Intangible assets, net | 54,082 | 58,970 |
Other non-current assets | 889 | 792 |
Total non-current assets | 57,733 | 63,631 |
Total assets | 128,863 | 136,463 |
Current liabilities: | ||
Accounts payable | 10,475 | 13,478 |
Accrued liabilities | 44,091 | 46,799 |
Short-term line of credit | 1,581 | 1,563 |
Current portion of debt | 15,135 | 85 |
Current portion of derivative warrant liabilities | 3,261 | 0 |
Other current liabilities | 9,146 | 7,090 |
Total current liabilities | 83,689 | 69,015 |
Non-current liabilities: | ||
Debt, net of current portion | 0 | 14,713 |
Derivative warrant liabilities | 8,609 | 6,403 |
Other non-current liabilities | 5,788 | 6,975 |
Total non-current liabilities | 14,397 | 28,091 |
Commitments and contingencies (note 13) | ||
Stockholders’ equity: | ||
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding | 0 | 0 |
Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,909 and 5,517,174 shares issued and outstanding, respectively | 1 | 1 |
Additional paid-in capital | 346,132 | 343,485 |
Accumulated deficit | (315,356) | (304,129) |
Total stockholders’ equity | 30,777 | 39,357 |
Total liabilities and stockholders’ equity | $ 128,863 | $ 136,463 |
 | Mr. Joshua R. Disbrow |
---|---|
 | https://aytubio.com |
 | Pharmaceuticals |
 | 164 |